Nothing Special   »   [go: up one dir, main page]

PT3204494T - Métodos melhorados de inativação de vírus da poliomielite, adsorção de adjuvante - Google Patents

Métodos melhorados de inativação de vírus da poliomielite, adsorção de adjuvante

Info

Publication number
PT3204494T
PT3204494T PT158312371T PT15831237T PT3204494T PT 3204494 T PT3204494 T PT 3204494T PT 158312371 T PT158312371 T PT 158312371T PT 15831237 T PT15831237 T PT 15831237T PT 3204494 T PT3204494 T PT 3204494T
Authority
PT
Portugal
Prior art keywords
improved methods
vaccine compositions
compositions obtained
dose reduced
reduced vaccine
Prior art date
Application number
PT158312371T
Other languages
English (en)
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of PT3204494T publication Critical patent/PT3204494T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/06Inactivation or attenuation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32311Enterovirus
    • C12N2770/32334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32661Methods of inactivation or attenuation
    • C12N2770/32663Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32671Demonstrated in vivo effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT158312371T 2014-10-07 2015-10-06 Métodos melhorados de inativação de vírus da poliomielite, adsorção de adjuvante PT3204494T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3180MU2014 2014-10-07

Publications (1)

Publication Number Publication Date
PT3204494T true PT3204494T (pt) 2020-07-10

Family

ID=55300742

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158312371T PT3204494T (pt) 2014-10-07 2015-10-06 Métodos melhorados de inativação de vírus da poliomielite, adsorção de adjuvante

Country Status (24)

Country Link
US (1) US10485862B2 (pt)
EP (2) EP3663396A1 (pt)
JP (2) JP6755243B2 (pt)
KR (2) KR102510744B1 (pt)
CN (2) CN106999569B (pt)
AU (2) AU2015334495B2 (pt)
CA (1) CA2963897C (pt)
CU (1) CU24510B1 (pt)
CY (1) CY1123078T1 (pt)
DK (1) DK3204494T3 (pt)
EA (1) EA201700187A1 (pt)
ES (1) ES2803578T3 (pt)
HU (1) HUE049104T2 (pt)
LT (1) LT3204494T (pt)
MX (1) MX2017004534A (pt)
MY (1) MY204389A (pt)
PE (1) PE20171132A1 (pt)
PH (1) PH12017500627A1 (pt)
PL (1) PL3204494T3 (pt)
PT (1) PT3204494T (pt)
SG (2) SG10202010814RA (pt)
SI (1) SI3204494T1 (pt)
UA (1) UA125788C2 (pt)
WO (1) WO2016063291A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3204494T (pt) * 2014-10-07 2020-07-10 Serum Institute Of India Pvt Ltd Métodos melhorados de inativação de vírus da poliomielite, adsorção de adjuvante
EP3454895B1 (en) 2016-05-10 2024-03-27 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
EA201900117A1 (ru) * 2016-08-26 2019-09-30 Серум Инститьют Оф Индиа Прайвит Лимитид Комбинированная вакцина и способ её производства (варианты)
TWI711700B (zh) * 2017-07-10 2020-12-01 印度商印度血清研究公司 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
US11478541B2 (en) 2017-11-03 2022-10-25 Takeda Vaccines, Inc. Method for inactivating Zika virus and for determining the completeness of inactivation
EP3717638A4 (en) 2017-11-30 2022-03-09 Takeda Vaccines, Inc. METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS
WO2019155492A1 (en) * 2018-02-07 2019-08-15 Bharat Biotech International Limited A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127847A (en) * 1996-07-02 2004-06-01 Connaught Lab Polio-karma vaccine vaccines, valuable pertussis
MX2007002372A (es) * 2004-08-27 2007-05-08 Panacea Biotec Ltd Vacuna para la poliomielitis inactivada derivada de la cepa sabin del virus de la polio.
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
SI2097102T1 (sl) * 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
CN100540662C (zh) * 2006-12-06 2009-09-16 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
BR112012014689B1 (pt) * 2009-12-16 2019-11-12 Serum Institute Of India Private Limited composição imunogênica
KR20140026392A (ko) * 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
PT3204494T (pt) * 2014-10-07 2020-07-10 Serum Institute Of India Pvt Ltd Métodos melhorados de inativação de vírus da poliomielite, adsorção de adjuvante

Also Published As

Publication number Publication date
US10485862B2 (en) 2019-11-26
EA201700187A1 (ru) 2017-12-29
CN113368227A (zh) 2021-09-10
AU2015334495B2 (en) 2021-08-19
KR20210021148A (ko) 2021-02-24
KR20170063947A (ko) 2017-06-08
CA2963897C (en) 2023-08-22
NZ731341A (en) 2023-11-24
MX2017004534A (es) 2017-10-11
CA2963897A1 (en) 2016-04-28
JP2020203906A (ja) 2020-12-24
EP3204494B1 (en) 2020-04-01
CU24510B1 (es) 2021-05-12
SG11201702838SA (en) 2017-05-30
KR102219638B1 (ko) 2021-02-23
CY1123078T1 (el) 2021-10-29
JP7063957B2 (ja) 2022-05-09
LT3204494T (lt) 2020-07-10
MY204389A (en) 2024-08-27
KR102510744B1 (ko) 2023-03-15
CU20170044A7 (es) 2018-09-05
AU2021269395B2 (en) 2024-05-23
BR112017007089A2 (pt) 2017-12-26
UA125788C2 (uk) 2022-06-08
AU2021269395A1 (en) 2021-12-16
JP2017533899A (ja) 2017-11-16
JP6755243B2 (ja) 2020-09-16
ES2803578T3 (es) 2021-01-28
EP3204494A1 (en) 2017-08-16
CN106999569A (zh) 2017-08-01
PL3204494T3 (pl) 2020-09-21
CN106999569B (zh) 2021-06-29
PH12017500627A1 (en) 2017-09-25
EP3663396A1 (en) 2020-06-10
SI3204494T1 (sl) 2020-08-31
PE20171132A1 (es) 2017-08-09
AU2015334495A1 (en) 2017-05-25
WO2016063291A1 (en) 2016-04-28
HUE049104T2 (hu) 2020-08-28
SG10202010814RA (en) 2020-12-30
DK3204494T3 (da) 2020-07-06
US20170348411A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
ZA201904717B (en) Therapeutic hpv18 vaccines
IL247309A0 (en) Preparations for inhibiting virus replication and methods for their preparation and use
IL315136A (en) Methods for treating or preventing asthma by adding an IL-4R antagonist
ZA201700952B (en) Indoles for use in influenza virus infection
SG11201702838SA (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
IL273932A (en) Methods of treatment and prevention of viral infection
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
HK1215864A1 (zh) 用於埋線療法的套管
IL251108A0 (en) Preparations and methods for the treatment of acute radiation syndrome
EP3166637A4 (en) Compositions and methods for treating dengue virus infection
PL3331359T3 (pl) Rolnicze kompozycje adiuwantowe i sposoby zastosowania takich kompozycji
PT3106459T (pt) Derivado da indolona substituído com pirrole, seu método de preparação, composição que compreende o mesmo e sua utilização
IL251101A0 (en) Vaccine compounds comprising tryptophan 3,2-dioxygenase or fragments thereof
PT3142641T (pt) Formulações para o tratamento de hipertiroidismo
PL3223846T3 (pl) Kompozycje adiuwantowe i powiązane sposoby
EP3166957A4 (en) Sulfated-glycolipids as adjuvants for vaccines
IL250553B (en) Means and method for targeted medical treatment using x-rays
PT3297666T (pt) Adjuvante e vacina molecular
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201406755D0 (en) Indigestion, angled adjustable bed
GB201419559D0 (en) Therapeutic compositions and methods
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes
GB201405857D0 (en) Immunogenic formulations
GB201411371D0 (en) Immunogenic composition